WAM
HZNP

Wealthspire Advisors (Maryland)’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-155
Closed -$2K – 2581
2017
Q2 		$2K Buy
155
+90
+138% +$1.12K ﹤0.01% 2039
2017
Q1 		$1K Hold
65
– – ﹤0.01% 1890
2016
Q4 		$1K Buy
+65
New +$1.18K ﹤0.01% 1718

Other funds holding HZNP

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Wealthspire Advisors (Maryland)'s HZNP Position: Q3 2017 in Review

Wealthspire Advisors (Maryland) sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2017, closing a stake of 155 shares — an estimated $2K sold.

Wealthspire Advisors (Maryland) first reported a position in HZNP in Q4 2016 and held it in 3 quarters. The position peaked at $2K in Q2 2017. 181 funds tracked by Wall St. Rank hold HZNP as of Q3 2017.

  • Wealthspire Advisors (Maryland) reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2017 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 155 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2017, an estimated $2K.
  • Wealthspire Advisors (Maryland) first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2016 and held it in 3 quarters.
  • Wealthspire Advisors (Maryland)'s Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2K in Q2 2017.
  • 181 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2017.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q3 2017, filed 8 Nov 2017.